Last reviewed · How we verify
DAPT on-target
DAPT (dual antiplatelet therapy) on-target inhibits platelet aggregation through simultaneous blockade of multiple platelet activation pathways to prevent thrombotic events.
DAPT (dual antiplatelet therapy) on-target inhibits platelet aggregation through simultaneous blockade of multiple platelet activation pathways to prevent thrombotic events. Used for Acute coronary syndrome (ACS) with percutaneous coronary intervention (PCI) and stent placement, Secondary prevention of stent thrombosis and recurrent myocardial infarction.
At a glance
| Generic name | DAPT on-target |
|---|---|
| Sponsor | Kaiser Franz Josef Hospital |
| Drug class | Antiplatelet combination therapy |
| Target | Cyclooxygenase (COX) and P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
DAPT combines two antiplatelet agents that work synergistically—typically aspirin (irreversible cyclooxygenase inhibitor) and a P2Y12 receptor antagonist (e.g., clopidogrel, prasugrel, or ticagrelor)—to prevent platelet activation and clot formation through complementary mechanisms. This combination is more effective than monotherapy at reducing stent thrombosis and recurrent ischemic events in cardiovascular disease.
Approved indications
- Acute coronary syndrome (ACS) with percutaneous coronary intervention (PCI) and stent placement
- Secondary prevention of stent thrombosis and recurrent myocardial infarction
Common side effects
- Bleeding (major and minor)
- Dyspepsia
- Bruising
- Gastrointestinal hemorrhage
Key clinical trials
- PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy (NA)
- OCT-based DAPT Cessation in HBR Patients (NA)
- Anti-inflammatory Therapy for Recurrent In-stent Restenosis (PHASE4)
- Impact of Potassium Competitive Acid Blockers After Percutaneous Coronary Intervention for Efficacy and Safety Outcome: Target Trial Emulation Study.
- Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial). (PHASE4)
- Ticagrelor Versus Clopidogrel for CMD in Patients With AMI: A Retrospective Study Based on the Angio-IMR
- Comparison Three vs Twelve Months of Dual Anti-Platelet Therapy After Stent Implantation (PHASE4)
- The IDEAL-PCI Extended Registry (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DAPT on-target CI brief — competitive landscape report
- DAPT on-target updates RSS · CI watch RSS
- Kaiser Franz Josef Hospital portfolio CI